** Shares of biotech firm Precision BioSciences DTIL.O rise 8.89% to $5.51 premarket
** Co posts Q4 profit of $1.05 per share, while analysts were expecting a loss of 54 cents per share, according to data compiled by LSEG
** Posts Q4 revenue of $34.2 million, beating analysts' estimate of $9.1 million
** Says revenue increase was driven mainly by $26.2 million booked under its Novartis collaboration deal and $8 million from the Imugene license agreement
** DTIL shares rose over 9% in 2025
(Reporting by Kunal Das in Bengaluru)
((Kunal.Das2@thomsonreuters.com;))